Company Description
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders.
The company’s lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation.
The company’s lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance.
The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016.
Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 2, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Shao-Lee Lin |
Contact Details
Address: 40 Guest Street Boston, Massachusetts 02135 United States | |
| Phone | 617 949 2680 |
| Website | cuebiopharma.com |
Stock Details
| Ticker Symbol | CUE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645460 |
| CUSIP Number | 22978P205 |
| ISIN Number | US22978P2056 |
| Employer ID | 47-3324577 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shao-Lee Lin M.D., Ph.D. | President, Chief Executive Officer and Director |
| Lucinda Warren | Principal Accounting Officer and Chief Business Officer |
| Colin G. Sandercock J.D., MSE | Senior Vice President of Intellectual Property |
| Dr. Ronald D. Seidel III, Ph.D. | Co-Founder |
| Dr. Rodolfo Jose Chaparro Ph.D. | Co-Founder |
| Dr. Steven C. Almo Ph.D. | Co-Founder and Chairman of Scientific and Clinical Advisory Board |
| James M. Ahlers | Chief Financial Officer |
| Agnes Lee | Chief Officer of Public and Investor Relations |
| Sumita Ray J.D. | Chief Legal and Compliance Officer and Corporate Secretary |
| Dr. Daniel G. Baker M.D., Ph.D. | Interim Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 21, 2026 | SCHEDULE 13D | Filing |
| Aug 20, 2026 | EFFECT | Notice of Effectiveness |
| Aug 14, 2026 | 144 | Filing |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 14, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SCHEDULE 13G | Filing |
| Aug 13, 2026 | 144 | Filing |
| Aug 12, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 3, 2026 | 8-K | Current Report |
| Jul 22, 2026 | D | Notice of Exempt Offering of Securities |